Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth P Johnson

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Therapeutics and Clinical Risk Management|April 28, 2010
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisKenneth P Johnson
The Neurologist|July 12, 2007
Natalizumab (Tysabri) treatment for relapsing multiple sclerosisKenneth P Johnson
Expert Review of Neurotherapeutics|March 28, 2012
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosisKenneth P Johnson
Expert Opinion on Drug Metabolism & Toxicology|April 20, 2010
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an updateKenneth P Johnson
Journal of the Neurological Sciences|March 14, 2007
Control of multiple sclerosis relapses with immunomodulating agentsKenneth P Johnson
Expert Review of Pharmacoeconomics & Outcomes Research|June 17, 2009
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosisKenneth P Johnson, Deborah L Due
The Patient|January 6, 2012
Burden of a multiple sclerosis relapse: the patient's perspectiveMerrikay Oleen-Burkey, Jane Castelli-Haley, Maureen J Lage, et al.
Advances in Therapy|May 16, 2009
Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosisJane Castelli-Haley, MerriKay A Oleen-Burkey, Maureen J Lage, et al.
Journal of Neuroimmunology|July 17, 2003
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotypeSuhayl Dhib-Jalbut, Man Chen, Areen Said, et al.
Journal of the Neurological Sciences|March 3, 2007
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid, Andrew D Goodman, Amy Weinstein, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Therapeutics and Clinical Risk Management|April 28, 2010
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisKenneth P Johnson
The Neurologist|July 12, 2007
Natalizumab (Tysabri) treatment for relapsing multiple sclerosisKenneth P Johnson
Expert Review of Neurotherapeutics|March 28, 2012
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosisKenneth P Johnson
Expert Opinion on Drug Metabolism & Toxicology|April 20, 2010
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an updateKenneth P Johnson
Journal of the Neurological Sciences|March 14, 2007
Control of multiple sclerosis relapses with immunomodulating agentsKenneth P Johnson
Expert Review of Pharmacoeconomics & Outcomes Research|June 17, 2009
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosisKenneth P Johnson, Deborah L Due
The Patient|January 6, 2012
Burden of a multiple sclerosis relapse: the patient's perspectiveMerrikay Oleen-Burkey, Jane Castelli-Haley, Maureen J Lage, et al.
Advances in Therapy|May 16, 2009
Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosisJane Castelli-Haley, MerriKay A Oleen-Burkey, Maureen J Lage, et al.
Journal of Neuroimmunology|July 17, 2003
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotypeSuhayl Dhib-Jalbut, Man Chen, Areen Said, et al.
Journal of the Neurological Sciences|March 3, 2007
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid, Andrew D Goodman, Amy Weinstein, et al.
Pageof 2